With tailor-made nanocarriers, we will set new standards for the targeted, efficient and low-risk use of active pharmaceutical ingredients and other highly potent substances for medical and life science applications.
OUR VISION
We save human lives
by targeted use of highly potent substances
We rethink therapy
via tailor-made nanocarriers for efficiency and safety
We treat the untreatable
e.g. septic liver failure
NEWS
2nd April 2025
CLINICAL PHASE I STUDY WITH POLYMERIC NANOPARTICLES STARTED
SmartDyeLivery’s Nanocarrier SDL-M1 was administered to humans for the first time. In the Phase I study, the safety and tolerability of the intravenously administered nanocarriers are being tested in healthy volunteers. SDL-M1 is the first application from SmartDyeLivery's technology platform and is designed to deliver an active substance specifically into the metabolic cells of the liver.
In order to align the positioning of our ‘first-in-class’ medication for septic cholestasis with the exact clinical target groups and needs, a Medical Advisory Board set up by SmartDyeLivery met for the first time in January. The expert panel...
A night full of amazement and experiments is over and attracted numerous visitors to the Long Night of Science. We are delighted with the many young and old revellers who...
